A Study of the Safety and Tolerance of Three Doses of G17DT in Metastatic Colorectal Cancer

Inclusion Criteria:

* Patients aged 18 years or over with histologically verified adenocarcinoma of colon or rectum.
* Recurrent of metastatic disease not amenable to curative surgery and/or radiotherapy.
* Life expectancy greater than 3 months.
* Karnofsky Index Score greater than or equal to 50%.
* Written informed consent obtained.

Exclusion Criteria:

* Neoplastic lesions other than colorectal cancer (except treated basal cell carcinoma of the skin or cancer of the uterine cervix, through Stage I.
* Acute intercurrent illness.
* Patient considered to be a medical risk because of non-malignant systemic disease or grossly abnormal laboratory results.
* Patients who had received any other anticancer therapy within 3 months.
* Factor liable to alter the serum gastrin concentration or affect intra-gastric acidity, for instance concomitant therapy with H2 receptor antagonist drugs, proton pump inhibitors, or previous gastric surgery.
* Patients immunologically compromised including those on corticosteroid therapy.
* Women of child-bearing age.
* Positive immediate hypersensitivity reaction to skin testing with study medication.
* Patients unable to complete the diary book
* Haematogical Status Haemoglobin count less than 10g/dL White Blood Cell count less than 4.0 x 10\^9/L Platelet count less than 100 x 10\^9/L